Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

Health ProfessionalsPatients

RecruitingLast updated: 19 January 2026

A drug called INCA036873 for treatment of clear cell renal cell carcinoma, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and T-cell lymphomasA Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Trial purpose

Medical clipboardCancer treatment

Tumor type

Multi-Cancer Multi-Cancer

Age

People18+

Clinical summary

Summary

This is a study to evaluate how safe and tolerable a drug called INCA036873 is in people with either:

  • clear cell renal cell carcinoma (ccRCC)
  • diffuse large B-cell lymphoma (DLBCL, NOS)
  • high-grade B-cell lympoma (HGBCL)
  • peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL)
  • Cutaneous T-cell lymphoma (CTCL, incl. MF or SS  ≥Stage IIB with B0/B1 blood involvement).

To be eligible, you must be experiencing disease progression, relapse or refractory to prior therapy.

The study has three parts which all consist of INCA036873 being administered intravenously (IV). The different parts will be determining and evaluating different dose levels of the drug. 

Eligibility

Inclusion

  • Age ≥18 years.
  • ECOG performance status of 0 or 1.

  • Histologically confirmed:

    • Clear cell renal cell carcinoma (ccRCC).
    • Diffuse large B-cell lymphoma (DLBCL, NOS).
    • High-grade B-cell lymphoma (HGBCL).
    • Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
    • Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).

  • Disease progression, relapse, or refractory to prior therapy:

    • ccRCC: ≥1 prior line incl. ICI + TKI.
    • DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
    • PTCL/CTCL: ≥1 prior systemic therapy.
  • Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
  • Tumor tissue available for central testing.

Exclusion

  • Untreated or progressive CNS disease unless previously treated and stable.
  • Other active invasive malignancy within 2 years (except certain low-risk cancers).
  • Prior CD70-targeting therapy, including CAR T.
  • ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
  • Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).
  • Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
  • Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.
  • Pregnancy, breastfeeding, or unwillingness to use effective contraception.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Inclusion

  • You have had treatment, but your cancer has come back (relapsed or recurrent).
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ClinicalTrials.gov, EU Clinical Trials Register *. View further details about this trial on the registry via the links below:

Trial sponsor

Incyte Corporation

Scientific Title

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait